Clinical trials: psoriasis
Psoriasis
A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring
This observational study aims to assess pregnancy and infant outcomes among pregnant women with psoriasis who have been exposed to deucravacitinib treatment in the USA.
- Trial name
- NCT06710470
- Testing
- Deucravacitinib, Systemic psoriasis medications, No systemic medications
- Where
- United States
- Volunteers
- 833 people
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis
A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting
The main purpose of this study to investigate the relationship between clinical symptoms and quality of life (QoL) in participants who receive Tildrakizumab in the frame of clinical routine for the treatment of moderate to severe…
- Trial name
- NCT06488170
- Testing
- Tildrakizumab
- Where
- 7 sites in Czechia
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Almirall, S.A.
Skin Lesions, Melanocytic Nevi
Evaluating an Artificial Intelligence Tool to Help Primary Care Doctors Diagnose Skin Conditions.
This study aims to determine if an artificial intelligence (AI) medical device can help primary care doctors more accurately identify and manage various skin conditions.
- Conditions
- Skin Lesions, Melanocytic Nevi, Melanoma (Skin Cancer), Basal Cell Carcinoma of Skin
- Trial name
- LegitHealth PH (NCT07428941)
- Testing
- AI-based medical device for aided diagnosis in dermatological conditions
- Where
- Spain
- Volunteers
- 9 people
- Sponsor
- AI Labs Group S.L
Psoriasis
Effect of Long-term Psoriasis on Patients' Life - CORONATE
Psoriasis, is an inflammatory chronic skin disease which has a heavy physical and psychosocial impact on participant's life. This is a study to finalize and validate a questionnaire to assess the long-term effect of long-term…
- Trial name
- CORONATE (NCT05555953)
- Where
- 15 sites in Italy
- Volunteers
- 543 people
- Sponsor
- AbbVie
Plaque Psoriasis
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in children and adolescent participants aged 4 to <18 years with moderate to severe plaque psoriasis.
- Trial name
- NCT04772079
- Testing
- Deucravacitinib
- Where
- 65 sites in Argentina, Australia and 11 more
- Volunteers
- 153 people
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis
Evaluation of TWEAK in Plaque Psoriasis and Psoriatic Arthritis Patients
Psoriasis vulgaris is associated with significant comorbidity including depression, increased risk of cardiovascular events, diminished quality of life, as well as overall increased mortality.
- Trial name
- NCT06370156
- Testing
- Adalimumab
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Egymedicalpedia
Psoriasis
A Randomized, Open, Parallel, Controlled, Multi-center, Interventional, Cross-sectional Study to Evaluate the Detection Rate of Psoriatic Arthritis in Korean Moderate-to-severe Psoriasis Patients, With or Without Active Screening for Arthritis in Psoriasis (ASAP Study)
This was a randomized, open, parallel, controlled, multi-center, interventional, cross-sectional study to evaluate the detection rate of Psoriatic arthritis (PsA) in Korean moderate to severe Psoriasis (PsO) patients with or…
- Trial name
- ASAP (NCT05758402)
- Testing
- Routine practice group, EARP group
- Where
- 15 sites in South Korea
- Volunteers
- 368 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.
- Trial name
- NCT07449702
- Testing
- ORKA-001
- Where
- 39 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Oruka Therapeutics, Inc.
Generalized Pustular Psoriasis
Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study
This study is open to people with generalized pustular psoriasis (GPP). People can only take part if they have completed treatment in a previous study with spesolimab (1368-0013 or 1368-0027).
- Trial name
- NCT03886246
- Testing
- Spesolimab
- Where
- 58 sites in United States, Argentina and 19 more
- Volunteers
- 131 people
- Sponsor
- LEO Pharma
Psoriasis, Rheumatoid Arthritis
BE Study in Patients - Methotrexate Tablets
To characterize the pharmacokinetic profile of the Test product - Methotrexate Tablets USP, 2.5 mg of Amneal Pharmaceuticals, compared to that of the corresponding Reference product - Methotrexate Tablets USP 2.5 mg manufactured…
- Trial name
- NCT02940561
- Testing
- Methotrexate - Amneal, Methotrexate - DAVA
- Where
- 3 sites in India
- Volunteers
- 48 people
- Sponsor
- Amneal Pharmaceuticals, LLC
Psoriasis
Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis
The purpose of this study is to evaluate the safety and efficacy of AN2728 Ointment B, 2.0% and 0.5%, compared to Ointment Vehicle B, applied once or twice daily for 12 weeks, in the treatment of plaque type psoriasis
- Trial name
- AN2728PSR203 (NCT01029405)
- Testing
- AN2728
- Where
- 5 sites in Mexico
- Volunteers
- 145 people
- Sponsor
- Pfizer
Generalized Pustular Psoriasis
A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)
This study is a multicenter, single-group, open-label study to evaluate the safety and tolerability of TQH2929 injection at a dose of 900mg in adult subjects with active Generalized Pustular Psoriasis (GPP), and to preliminarily…
- Trial name
- NCT06433531
- Testing
- TQH2929 Injection
- Where
- 7 sites in China
- Volunteers
- 9 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Psoriasis
A Study of Guselkumab Given After Ustekinumab in Participants With Moderate to Severe Psoriasis in Routine Clinical Practice
The main purpose of this study is to describe how well Guselkumab works after switching from Ustekinumab in participants with moderate to severe psoriasis in a routine clinical setting.
- Trial name
- G-START (NCT07746583)
- Where
- Hungary
- Volunteers
- 100 people
- Sponsor
- Janssen-Cilag Kft.
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)
This study is being conducted to evaluate the efficacy and safety/tolerability of subcutaneous tildrakizumab (MK-3222), followed by an optional long-term safety extension study, in participants with moderate-to-severe chronic…
- Trial name
- reSURFACE 1 (NCT01722331)
- Testing
- Tildrakizumab 200 mg, Tildrakizumab 100 mg
- Volunteers
- 772 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Psoriasis
A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis
This study is a multicenter, randomized, double-blind, placebo- and active-controlled Phase III clinical trial sponsored by Nanjing Shunxin Pharmaceutical Co., Ltd., a subsidiary of Chiatai Tianqing Pharmaceutical Group.
- Trial name
- NCT07724366
- Testing
- TQH3906 capsules, Deucravacitinib tablets 6 mg
- Where
- 45 sites in China
- Volunteers
- 400 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Moderate to Severe Chronic Plaque Psoriasis
Community Based Trial for AMEVIVE®
To evaluate the safety of treating subjects with up to 12 additional doses of alefacept.
- Trial name
- NCT00168753
- Testing
- Alefacept
- Where
- 36 sites in United States
- Volunteers
- 114 people
- Sponsor
- Astellas Pharma Inc
Psoriasis
A Study of LY3361237 in Participants With Psoriasis
The main purpose of this study is to learn more about the safety and tolerability of LY3361237 and any side effects that might be associated with it when given to participants with psoriasis.
- Trial name
- NCT04975295
- Testing
- LY3361237
- Where
- 7 sites in Bulgaria, Hungary and 2 more
- Volunteers
- 21 people
- Sponsor
- Eli Lilly and Company
Psoriatic Plaque
A Study to Investigate Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis
The study is designed to investigate efficacy and safety of KBL697 in patients with Moderate Plaque Type Psoriasis. KBL697 has been developed as a potential new treatment for Psoriatic Plaque.
- Trial name
- NCT04911751
- Testing
- KBL697
- Where
- 10 sites in United States, Australia
- Volunteers
- 80 people
- Sponsor
- KoBioLabs
Psoriasis
Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis
Merrimack is conducting a research study to see if an experimental drug, called MM-093, is safe and effective in the treatment of psoriasis.
- Trial name
- NCT00147329
- Testing
- MM-093
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Merrimack Pharmaceuticals
Psoriasis Vulgaris
A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris
An international, multi-centre, prospective, randomised, double-blind, 4-arm, placebo controlled, parallel group study with 12 weeks once daily oral treatment in subjects with psoriasis vulgaris.
- Trial name
- NCT01116895
- Testing
- LEO 22811
- Where
- 2 sites in Canada, France
- Volunteers
- 63 people
- Sponsor
- LEO Pharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.